# Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

> **NCT03605719** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pelareorep

## Key facts

- **NCT ID:** NCT03605719
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605719, "Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03605719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*